Journal
OBESITY
Volume 24, Issue 4, Pages 908-916Publisher
WILEY
DOI: 10.1002/oby.21448
Keywords
-
Categories
Funding
- Diabetes Australia Research Trust (Millennium Grant)
- St. Vincent's Clinic Foundation Grant
- OIS Program of the Victorian Government
- Garvan Research Foundation, Australia
Ask authors/readers for more resources
ObjectiveAlterations in lipids in muscle and plasma have been documented in insulin-resistant people with obesity. Whether these lipid alterations are a reflection of insulin resistance or obesity remains unclear. MethodsNondiabetic sedentary individuals not treated with lipid-lowering medications were studied (n=51). Subjects with body mass index (BMI)>25 kg/m(2) (n=28) were stratified based on median glucose infusion rate during a hyperinsulinemic-euglycemic clamp into insulin-sensitive and insulin-resistant groups (above and below median, obesity/insulin-sensitive and obesity/insulin-resistant, respectively). Lean individuals (n=23) served as a reference group. Lipidomics was performed in muscle and plasma by liquid chromatography electrospray ionization-tandem mass spectrometry. Pathway analysis of gene array in muscle was performed in a subset (n=35). ResultsIn muscle, insulin resistance was characterized by higher levels of C18:0 sphingolipids, while in plasma, higher levels of diacylglycerol and cholesterol ester, and lower levels of lysophosphatidylcholine and lysoalkylphosphatidylcholine, indicated insulin resistance, irrespective of overweight/obesity. The sphingolipid metabolism gene pathway was upregulated in muscle in insulin resistance independent of obesity. An overweight/obesity lipidomic signature was only apparent in plasma, predominated by higher triacylglycerol and lower plasmalogen species. ConclusionsMuscle C18:0 sphingolipids may play a role in insulin resistance independent of excess adiposity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available